Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.
Clinical Trials
6
3 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
2
33.3%
Available
1
16.7%
Completed
2
33.3%
Enrolling By Invitation
1
16.7%
No approval data available
- The developmental and epileptic encephalopathies (DEE) market reached USD 2.2 billion across the 7MM in 2025, with the United States accounting for approximately 59% of the total market share. - The diagnosed prevalent population of DEE in the 7MM is projected to rise from approximately 288,000 in 2025 to 326,000 by 2036, reflecting improved genetic testing and diagnostic awareness. - A robust pipeline featuring antisense oligonucleotides, gene therapies, and precision medicines—including zorevunersen, bexicaserin, and relutrigine—is expected to reshape the treatment landscape for genetically defined DEE subtypes. - Praxis Precision Medicines' relutrigine received FDA Priority Review acceptance in March 2026 with a PDUFA target action date of September 27, 2026, for SCN2A and SCN8A DEEs.
- Bright Minds Biosciences completed a $175 million public offering to fund clinical trials for its lead epilepsy drug BMB-101, which targets childhood epilepsy through selective serotonin 5-HT2C receptor activation. - The company's BMB-101 compound is designed to avoid the cardiac and psychedelic side effects that plagued previous drugs like fenfluramine by selectively targeting the 2C receptor while avoiding 2A and 2B receptors. - Phase II trial results for BMB-101 in developmental epileptic encephalopathies and absence epilepsy are expected around the end of this year, with the company's stock having appreciated approximately 5,000% over the past 12 months. - Recent acquisitions in the epilepsy space, including Lundbeck's $2.6 billion purchase of Longboard Pharmaceuticals for a similar serotonin 2C mechanism drug, highlight strong industry interest in this therapeutic approach.
• A new report offers an overview of the clinical trial landscape for Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy, providing key data and analysis. • The review includes data on trial numbers, average enrollment, and top countries involved, segmented by region, phase, status, endpoints, and sponsor type. • Key companies like Jazz Pharmaceuticals, UCB, Takeda, and others are profiled, with details on their ongoing trials and prominent drugs in development for Dravet Syndrome. • The report identifies trends in clinical trial enrollment over the past five years and highlights recent news related to Dravet Syndrome research and development.
- Bexicaserin demonstrated a 59.3% median reduction in countable motor seizures over 12 months in patients with developmental and epileptic encephalopathies (DEEs). - The PACIFIC open-label extension study showed consistent seizure reduction in both patients who switched from placebo to bexicaserin and those who continued treatment. - Longboard Pharmaceuticals, now acquired by Lundbeck, is advancing bexicaserin into Phase 3 trials, including the DEEp SEA study for Dravet syndrome. - Bexicaserin's favorable safety profile and tolerability were maintained throughout the 12-month extension, supporting its potential as a treatment for DEEs.
- Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN study to evaluate bexicaserin for seizures associated with developmental and epileptic encephalopathies (DEEs). - The global, double-blind, placebo-controlled trial will monitor countable motor seizures in approximately 320 participants aged two years and above. - Bexicaserin, a 5-HT2C receptor superagonist, has received breakthrough status from the FDA for this indication, addressing a critical unmet need in DEE treatment. - Eligible participants can join a 52-week open-label extension after the 12-week maintenance period, further assessing the drug's long-term safety and efficacy.
- Longboard Pharmaceuticals has initiated the Phase 3 DEEp OCEAN study to evaluate bexicaserin for seizures associated with Developmental and Epileptic Encephalopathies (DEEs). - The DEEp OCEAN trial is a global, double-blind, placebo-controlled study involving approximately 320 participants aged two to 65 years. - Bexicaserin, a selective 5-HT2C receptor superagonist, has received Breakthrough Therapy designation from the FDA for DEEs. - The study aims to address a crucial unmet need in the DEE community by providing access to innovative medications and tailored clinical trials.
- Longboard Pharmaceuticals initiated a Phase 3 clinical trial, DEEp SEA, to evaluate bexicaserin in Dravet syndrome patients aged 2-65 years. - Bexicaserin received Orphan Drug and Rare Pediatric Disease designations from the FDA for treating Dravet syndrome, highlighting its potential impact. - The EMA's Paediatric Committee issued a positive opinion on the Paediatric Investigation Plan for bexicaserin in children as young as two years old. - Lundbeck A/S is set to acquire Longboard, marking a strategic move to further develop novel neurological disease treatments.
- Longboard Pharmaceuticals has started a Phase 3 clinical trial, DEEp SEA, to assess bexicaserin in Dravet syndrome patients aged 2-65 years. - Bexicaserin, a selective 5-HT2C receptor superagonist, continues to show sustained seizure reduction and a favorable safety profile in DEEs. - The FDA granted Orphan Drug and Rare Pediatric Disease designations to bexicaserin for treating Dravet syndrome, highlighting its potential impact. - H. Lundbeck A/S is set to acquire Longboard, a strategic move following positive developments in bexicaserin's clinical program.
- Over 90 epilepsy treatment therapies are under development by more than 75 companies globally, targeting various mechanisms of action and routes of administration. - Longboard Pharmaceuticals reported positive Phase Ib/IIa results for LP352 (bexicaserin) in developmental and epileptic encephalopathies (DEEs), showing a significant reduction in seizure frequency. - Amzell has initiated a study comparing AMZ002 with Vigabatrin for treating infantile spasms, a rare and severe form of epilepsy, to assess efficacy and safety. - Emerging therapies like RLS103, CT-010, Darigabat, and XEN496 are in different clinical trial phases, indicating potential advancements in epilepsy management.
- Lundbeck will acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, a promising drug for developmental and epileptic encephalopathies (DEEs). - Bexicaserin, a 5-HT2C receptor superagonist, has shown encouraging results in clinical trials for reducing seizure frequency in Dravet syndrome and other DEEs. - The acquisition aligns with Lundbeck's strategy to expand its neuro-rare disease portfolio, with bexicaserin potentially launching in 2028 and reaching peak sales of $1.5-2 billion. - The deal is expected to close in the fourth quarter of 2024, pending regulatory approvals and tender of Longboard's outstanding shares.
